Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TEAD4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | TEAD4 Full-Length & Central Domain Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Ideal for palmitoylation-binding and YAP-interaction assays. |
View TEAD4 Products |
| Antigen (Mutant) | TEAD4 C359S Mutant Protein Palmitoylation-site mutant for covalent inhibitor mechanism validation. Sequence Verified. |
View TEAD4 Products |
| Interaction Partner | YAP1 Recombinant Protein (PDZ-binding domain) For YAP-TEAD4 disruption assays. HEK293 Expressed. |
View YAP1 Products |
| Gene Delivery | TEAD4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and reporter gene assays. |
View TEAD4 Products |
| Benchmark Ab | Anti-TEAD4 Recombinant Rabbit mAb Sequence Verified positive control for Western blot, IP, and ChIP applications. |
View TEAD4 Products |
| Validator | TEAD4 siRNA Set (3 unique sequences) For knockdown verification and specificity controls in functional assays. |
View TEAD4 Products |
| Related Target A | YAP1 Direct transcriptional co-activator; essential for TEAD4-driven gene expression. Recombinant YAP1 proteins and antibodies available. |
View YAP1 Products |
| Related Target B | TEAD1 Paralog family member for selectivity counter-screening and off-target liability assessment. |
View TEAD1 Products |
| Related Target C | LATS2 Upstream Hippo kinase regulating YAP/TAZ nuclear localization. Functional kinase proteins for pathway reconstitution. |
View LATS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity & Off-Target Liability (TEAD1/2/3/4) | Human TEAD paralog panel (>95% purity, Sequence Verified) for orthogonal binding and cellular selectivity assays. |
| Drug Resistance Mutant Surveillance | Custom mutant proteins (e.g., lipid-pocket variants) expressed in HEK293 and E. coli systems; Sequence Verified. |
| Covalent Binding Mechanism Validation | TEAD4 C359S Mutant Protein (Palmitoylation-deficient) available as negative control for covalent vs reversible inhibitor characterization. |
| YAP-TEAD4 Affinity Quantification | Human YAP1 (aa 50-171) & TEAD4 (aa 210-427) with verified purity >95%, suitable for SPR/BLI. |
| Palmitoylation Pocket Structural Integrity | Sequence Verified, native-like folding of the YAP-binding domain (YBD) to support autopalmitoylation assays. |
| Lack of Robust Cellular Controls | Lentiviral vectors for rapid generation of TEAD-responsive luciferase reporter cell lines. |
| Off-Target False Positives | Sequence-validated siRNA sets included for orthogonal specificity and target validation. |
Live TEAD4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TEAD4 therapeutics is intensifying, with major players shifting focus from upstream kinase inhibitors to direct disruption of the YAP/TAZ-TEAD transcriptional complex. First-generation pan-TEAD autopalmitoylation inhibitors (e.g., VT3989 from Vivace, IK-930 from Ikena) have entered Phase I/II clinical trials for NF2-deficient cancers and malignant pleural mesothelioma. As these programs advance, the next wave of R&D is targeting isoform-specific interactions (TEAD4 vs TEAD1 selectivity) to mitigate potential renal toxicity associated with TEAD1 inhibition. Furthermore, combination strategies with KRAS G12C inhibitors, EGFR-TKIs, and MEK inhibitors are gaining momentum, as Hippo pathway hyperactivation is a well-documented mechanism of acquired resistance in solid tumors. The emergence of resistant mutations within the lipid-binding pocket (e.g., rs11550887) underscores the need for novel allosteric inhibitors and PROTACs that can overcome escape mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Palmitoylation Inhibitor) | Vivace Therapeutics, Ikena Oncology | Mesothelioma, NF2-mutant Cancers | Selectivity Assay (Need High-Purity TEAD1-4 Panel) |
| Small Molecule (PPI Inhibitor) | Novartis, BridgeBio | Advanced Solid Tumors | YAP-TEAD Interaction Assay (Need Co-activator Proteins) |
| Targeted Protein Degrader (PROTAC) | Emerging Biotechs | Drug-Resistant Cancers | Ternary Complex Validation (Need Sequence Verified Domains) |
| Peptide/Peptidomimetic | Academic/Start-up Consortia | YAP-driven Malignancies | Affinity Binding SPR (Need Endotoxin-Controlled Antigens) |
| Pan-TEAD Inhibitor | Bristol Myers Squibb, Novartis | Solid Tumors (Broad) | Isoform Selectivity Panel (TEAD1-4) with Sequence Verified proteins |